Compile Data Set for Download or QSAR
Report error Found 295 Enz. Inhib. hit(s) with all data for entry = 11452
TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM616977(US11753403, Compound I-1)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617018(US11753403, Compound I-2)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617058(US11753403, Compound I-3)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617098(US11753403, Compound I-100)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617104(US11753403, Compound I-101)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617106(US11753403, Compound I-6)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617107(US11753403, Compound I-103)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617109(US11753403, Compound I-7)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617110(US11753403, Compound I-104)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617119(US11753403, Compound I-107)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617122(US11753403, Compound I-108)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617131(US11753403, Compound I-111)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617132(US11753403, Compound I-208)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617135(US11753403, Compound I-209)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617138(US11753403, Compound I-210)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617139(US11753403, Compound I-17)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617142(US11753403, Compound I-18)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617144(US11753403, Compound I-212)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617145(US11753403, Compound I-19)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617147(US11753403, Compound I-213)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617148(US11753403, Compound I-20)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617154(US11753403, Compound I-215)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617155(US11753403, Compound I-22)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617157(US11753403, Compound I-216)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617158(US11753403, Compound I-23)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617160(US11753403, Compound I-217)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617164(US11753403, Compound I-25)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617165(US11753403, Compound I-126)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617170(US11753403, Compound I-27)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617186(US11753403, Compound I-225)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617192(US11753403, Compound I-226)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617202(US11753403, Compound I-229)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617207(US11753403, Compound I-138)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617214(US11753403, Compound I-233)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617220(US11753403, Compound I-142)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617222(US11753403, Compound I-235)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617225(US11753403, Compound I-236)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617228(US11753403, Compound I-237)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617238(US11753403, Compound I-47)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617240(US11753403, Compound I-241)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617241(US11753403, Compound I-48)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617243(US11753403, Compound I-242)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617244(US11753403, Compound I-49)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617246(US11753403, Compound I-243)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617250(US11753403, Compound I-244)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617251(US11753403, Compound I-51)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617254(US11753403, Compound I-52)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617259(US11753403, Compound I-247)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617262(US11753403, Compound I-248)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617263(US11753403, Compound I-55)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 295 total ) | Next | Last >>
Jump to: